Phase III Trial PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib with Nivolumab in Metastatic Untreated Renal Cell Cancer

PROTOCOL: Alliance-A031704 SCHEMA A031704 Please Note: Below is partial eligibility, for full eligibility requirement’s,  please contact GHCI Research Department at (810) 762-8181, (810) 762-8079 and/or (810) 762-8038. Thank you! ELIGIBILITY: Histologic Documentation: Histologically documented renal cell carcinoma with clear cell component, including patients who have sarcomatoid features.  Stage: Any metastatic disease, including visceral, lymph node, […]